Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH): Results of a Responder Analysis

被引：0

作者：

Harari, S. ^{[1
,2
]}

Nathan, S. D. ^{[3
]}

Behr, J. ^{[4
]}

Wuyts, W. A. ^{[5
]}

Kirchgaessler, K. ^{[6
]}

Bengus, M. ^{[6
]}

Gilberg, F. ^{[6
]}

Wells, A. U. ^{[7
]}

机构：

[1] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy

[2] Osped San Giuseppe, Dept Med, Milan, Italy

[3] Inova Fairfax Hosp, Inova Heart & Vasc Inst, Falls Church, VA USA

[4] LMU & Asklepios Fachkliniken Gauting, Dept Internal Med, Comprehens Pneumol Ctr, Munich, Germany

[5] Univ Leuven, Dept Pulm Med, Unit Interstitial Lung Dis, Leuven, Belgium

[6] F Hoffmann Roche Ltd, Basel, Switzerland

[7] Royal Brompton Hosp, Interstitial Lung Dis Unit, London, England

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2022年 / 205卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A2434

引用

页数：1

共 50 条

[21] Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
Ulrich Costabel
Carlo Albera
Marilyn K. Glassberg
Lisa H. Lancaster
Wim A. Wuyts
Ute Petzinger
Frank Gilberg
Klaus-Uwe Kirchgaessler
Paul W. Noble
Respiratory Research, 20
[22] Pirfenidone in patients with advanced idiopathic pulmonary fibrosis: First experience
Hoet, Filip
Yzerbyt, Jonas
Wuyts, Wim A.
EUROPEAN RESPIRATORY JOURNAL, 2016, 48
[23] Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial
Kolb, Martin
Wells, Athol
Behr, Juergen
Richeldi, Luca
Schinzel, Birgit
Quaresma, Manuel
Stowasser, Susanne
Raghu, Ganesh
Martinez, Fernando J.
EUROPEAN RESPIRATORY JOURNAL, 2018, 52
[24] Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil
White, Eric
Crestani, Bruno
Guenther, Andreas
Maher, Toby M.
Ittrich, Carina
Diefenbach, Claudia
Rohr, Klaus B.
Quaresma, Manuel
Kolb, Martin
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[25] Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone
Donato Lacedonia
Michele Correale
Lucia Tricarico
Giulia Scioscia
Silvia Romana Stornelli
Filomena Simone
Massimo Casparrini
Natale Daniele Brunetti
Maria Pia Foschino Barbaro
Internal and Emergency Medicine, 2022, 17 : 815 - 822
[26] Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone
Lacedonia, Donato
Correale, Michele
Tricarico, Lucia
Scioscia, Giulia
Stornelli, Silvia Romana
Simone, Filomena
Casparrini, Massimo
Brunetti, Natale Daniele
Barbaro, Maria Pia Foschino
INTERNAL AND EMERGENCY MEDICINE, 2022, 17 (03) : 815 - 822
[27] IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
Duck, Annette
Pigram, Lucy
Errhalt, Peter
Ahmed, Deeba
Chaudhuri, Nazia
ADVANCES IN THERAPY, 2015, 32 (02) : 87 - 107
[28] HEPATIC DISORDERS OF PIRFENIDONE OR NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) A SYSTEMATIC REVIEW
Singla, D.
Mahapatra, S.
Dey, A.
John, A.
VALUE IN HEALTH, 2022, 25 (12) : S218 - S218
[29] PIRFENIDONE IS EFFICACIOUS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) WITH MORE PRESERVED LUNG FUNCTION
Noble, P. W.
Bradford, W. Z.
Costabel, U.
Glaspole, I.
Glassberg, M. K.
Gorina, E.
Kardatzke, D.
Lancaster, L.
Lederer, D. J.
Nathan, S. D.
Pereira, C.
Spirig, D.
Swigris, J. J.
Valeyre, D.
Albera, C.
THORAX, 2015, 70 : A81 - A81
[30] The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Valeyre, Dominique
Albera, Carlo
Bradford, Williamson
Costabel, Ulrich
King, Talmadge
Noble, Paul
Sahn, Steven
du Bois, Roland
EUROPEAN RESPIRATORY JOURNAL, 2012, 40

← 1 2 3 4 5 →